Different association of atherogenic index of plasma with the risk of high platelet reactivity according to the presentation of acute myocardial infarction

Sci Rep. 2024 May 13;14(1):10894. doi: 10.1038/s41598-024-60999-3.

Abstract

This study evaluated the association of atherogenic index of plasma (AIP) with platelet reactivity and clinical outcomes according to acute myocardial infarction (AMI). The composite of 3-year adverse outcomes of all-cause death, myocardial infarction, and cerebrovascular accident was evaluated in 10,735 patients after successful percutaneous coronary intervention with drug-eluting stents. AIP was defined as the base 10 logarithm of the ratio of triglyceride to high-density lipoprotein cholesterol concentration. High platelet reactivity (HPR) was defined as ≥ 252 P2Y12 reactivity unit. An increase of AIP (per-0.1 unit) was related to the decreased risk of HPR [odds ratio (OR) 0.97, 95% confidence interval (CI) 0.96-0.99; P = 0.001] in non-AMI patients, not in AMI patients (OR 0.98, 95% CI 0.96-1.01; P = 0.138). The HPR was associated with the increased risk of composite outcomes in both non-AMI and AMI patients (all-P < 0.05). AIP levels were not independently associated with the risk of composite outcomes in both patients with non-AMI and AMI. In conclusion, an inverse association between AIP and the risk of HPR was observed in patients with non-AMI. This suggests that the association between plasma atherogenicity and platelet reactivity may play a substantial role in the development of AMI.Trial registration: NCT04734028.

Keywords: Acute myocardial infarction; Drug-eluting stents; Percutaneous coronary intervention; Plasma atherogenicity; Platelet reactivity; Prognosis.

MeSH terms

  • Aged
  • Atherosclerosis* / blood
  • Blood Platelets* / metabolism
  • Cholesterol, HDL / blood
  • Drug-Eluting Stents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction* / blood
  • Percutaneous Coronary Intervention
  • Platelet Activation
  • Risk Factors
  • Triglycerides / blood

Substances

  • Triglycerides
  • Cholesterol, HDL

Associated data

  • ClinicalTrials.gov/NCT04734028